Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04913805 · ClinicalTrials.gov registry record · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
A Phase 2 study of Heart Failure With Preserved Ejection Fraction, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT04913805: Recruiting Phase 2 study of Heart Failure With Preserved Ejection Fraction, sponsored by University of Pennsylvania.
NCT04913805 is a Phase 2 study of Heart Failure With Preserved Ejection Fraction that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 53 participants, below the 2,287-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04913805, a Phase 2 study of Heart Failure With Preserved Ejection Fraction, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test whether pharmacologic agents that increase perfusion \[Potassium Nitrate (KNO3)\], with and without additional supplements that may improve mitochondrial function \[Propionyl-L-Carnitine (PLC) and Nicotinamide Riboside (NR)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
Primary Outcome
Time to exhaustion while exercising at 75% of peak workload
Conditions Studied
Interventions
- DRUG Potassium Nitrate
- DRUG Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside
- OTHER Potassium Chloride
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2021-10-11 |
| Est. Completion | 2027-05-01 |
| Phase | Phase 2 |
What NCT04913805 shows while recruiting
NCT04913805 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 2,287-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 3 interventions - of which Potassium Nitrate is the first listed.
NCT04913805 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04913805 about?
NCT04913805 is a clinical study titled "Matching Perfusion and Metabolic Activity in HFpEF". This study will test whether pharmacologic agents that increase perfusion \[Potassium Nitrate (KNO3)\], with and without additional supplements that may improve mitochondrial function \[Propionyl-L-Carnitine (PLC) and Nicotinamide Riboside (NR)\], improve submaximal exercise endurance and skeletal m...
What is the current status of trial NCT04913805?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2021-10-11. Estimated completion is 2027-05-01.
What conditions does trial NCT04913805 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction.
What interventions are being tested in trial NCT04913805?
The interventions under investigation include: Potassium Nitrate (DRUG), Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside (DRUG), Potassium Chloride (OTHER).
Who is sponsoring clinical trial NCT04913805?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04913805 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Preserved Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04913805's enrollment target sits among peer trials
53 26th of 42 higher than 16 of 42 other Heart Failure With Preserved Ejection Fraction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Preserved Ejection Fraction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
RECRUITING · Phase 2
-
Study of JK07 in Patients With Chronic Heart Failure
RECRUITING · Phase 2
-
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
RECRUITING · Phase 2
-
A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
RECRUITING · Phase 2
-
Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction
ACTIVE NOT RECRUITING · Phase 2
-
Cilostazol for HFpEF
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT05045950 · 53 participants · Phase 2
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI